![]() |
市场调查报告书
商品编码
1827703
2025年血液培养检测全球市场报告Blood Culture Tests Global Market Report 2025 |
近年来,血液培养检测市场规模迅速扩张,从2024年的67.9亿美元成长到2025年的75.1亿美元,复合年增长率为10.5%。预测期内的成长归因于感染疾病率的上升、人口老化、医疗基础设施的进步、研发的不断加强。
预计未来几年血液培养检测市场将快速成长,到2029年将达到129亿美元,复合年增长率为14.5%。预测期内的成长主要源自于医院内感染的增加、照护现场(POC) 需求的不断增长、医疗保健支出的不断增长以及监管部门的核准。预测期内的主要趋势包括远端医疗和远端检测、自动化和人工智慧、多重检测、败血症管理以及感染疾病监测。
血液培养是用于识别血液中致病微生物的诊断程序。这些检测在检测血液样本中由各种微生物(包括细菌、酵母菌和其他外来生物)引起的感染疾病方面发挥着重要作用。
血液培养检测主要采用传统/手动和自动化方法。传统或手动方法用于检测血液检体中的细菌、酵母菌和其他微生物等入侵者。手动检测需要熟练的人员进行实际检测并解释结果。血液培养产品包括利用基于培养的技术、分子技术、微阵列、PCR(聚合酵素链锁反应)、PNA-FISH(肽核酸萤光原位杂合反应)和蛋白质组学技术的耗材、设备、软体和服务。这些技术用于检测菌血症、真菌血症和分枝桿菌感染疾病。血液培养检测通常用于医院实验室、参考实验室、学术实验室和其他检测机构。
2025年春季美国关税突然上调及其引发的贸易摩擦,对医疗设备领域产生了重大影响,尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制涨价,製造商面临利润压力。监管挑战进一步加剧了形势,因为由于关税而更换供应商通常需要医疗设备重新认证,导致市场准入延迟。为此,企业正在透过双重采购关键零件、增加标准化产品的国内生产以及加快寻找更具成本效益的材料来降低风险。
本研究报告是商业研究公司 (The Business Research Company) 新报告系列的一部分,该系列提供血液培养检测市场统计数据,例如全球市场规模、区域份额、血液培养检测市场份额的竞争对手、详细的血液培养检测细分市场、市场趋势和机会,以及您在血液培养检测行业取得成功所需的数据。本血液培养检测市场研究报告对该行业的现状和未来趋势进行了详细分析,为您提供所需的一切观点。
未来五年的预测成长率为14.5%,较我们先前对该市场的预测略有下降0.2%。下降的主要原因是美国与其他国家之间的关税影响。这项影响将透过对来自比利时和瑞典等主要地区的富集培养基和自动检测感测器征收关税直接影响美国,这可能导致败血症诊断试剂供应减少,检测成本上升。由于互惠关税以及贸易紧张局势和限制加剧对全球经济和贸易的负面影响,这项影响也将更加广泛。
感染疾病率的上升预计将推动血液培养检测市场的成长。感染疾病是由病毒、细菌、真菌和寄生虫等病原体引起的。这些有害微生物从外部或透过与受感染者接触进入人体。 COVID-19、结核病、流感、麻疹、爱滋病毒和链球菌性感染疾病等疾病会导致暂时不适、严重组织损伤甚至死亡。世界卫生组织 (WHO) 已将感染疾病确定为全球第二大死因。感染疾病的增加推动了对血液培养检测的需求,以确定患者是否患有可能危及生命的菌血症或败血症。例如,根据英国卫生安全局 2024 年 8 月的报告,截至 2022 年 12 月 31 日,英国。截至 2023 年 5 月 31 日,已通报新增 21 例病例,主要在英格兰,苏格兰通报 1 例。因此,感染疾病的盛行率不断上升,推动了对血液培养测试的需求。
抗生素抗药性细菌的增加预计将推动未来血液培养检测市场的成长。抗生素抗药性是指细菌、病毒和其他微生物抵抗以前可有效治疗其引起的感染疾病的抗生素和抗菌药物的作用的能力。抗生素抗药性感染疾病的增加需要更全面的诊断测试,包括血液培养测试,以确定最有效的治疗方法。例如,根据美国政府间组织世界卫生组织 (WHO) 2023 年 11 月的报告,抗生素抗药性感染疾病预计将从 2030 年的 1 兆美元增加到 2050 年的 1 兆至 3.4 兆美元之间。因此,抗生素抗药性增加导致的需求不断增长,促进了血液培养检测市场的成长。
技术创新已成为影响血液培养检测市场的突出趋势。在製药、生技药品、营养保健品和医疗设备等充满活力的产业格局中,技术创新是满足不断变化的产业需求的关键。高效且经济地将新产品推向市场的迫切需求促使製造商开发尖端的血液培养检测技术。值得注意的是,Labcorp 于 2022 年 5 月推出了 Labcorp OnDemand™ 家用采集试剂套件。这款创新试剂套件利用干血技术从少量血液样本中测量糖化血红蛋白 (HbA1c),为使用者提供随时间推移的平均血糖值洞察。这些技术进步不仅提高了准确性和安全性,还使人们能够舒适地在家中方便地监测自己的健康状况,进一步推动了血液培养检测市场的成长。
有机血液培养检测市场的主要企业正致力于开发先进技术,例如临床化学技术,旨在透过提供综合检测解决方案来提高诊断准确性、缩短週转时间并加强患者管理,从而全面洞察感染疾病及相关健康问题。临床化学技术是指主要用于分析体液(例如血液)以测量化学成分和评估健康状况的诊断方法和设备。例如,2024年4月,总部位于中国的医疗医疗设备公司迈瑞医疗国际有限公司推出了一个中型实验室。这些创新体现了迈瑞致力于支持中型实验室的决心,透过提供简单有效的解决方案来增强诊断能力,同时满足医疗专业人员日益增长的需求。
2022年4月,总部位于印度的体外诊断解决方案提供商BioMerieux India Pvt Ltd收购了Specific Diagnostics,收购金额未揭露。此次收购旨在透过提供创新的体外诊断解决方案来改善公众健康。 Specific Diagnostics是一家总部位于印度的公司,生产SPECIFIC REVEAL Rapid AST系统。
血液培养检测市场的主要企业包括 Becton、Dickinson and Company、BioMerieux SA、Thermo Fisher Scientific Inc.、Luminex Corporation、Danaher Corporation、Terumo Corporation、Bruker Corporation、F. Hoffmann-La Roche AG、Biobase Biotech Co. Ltd.、Scenker Biological Technology Co. Ltd.、Bull AG、Ahx、as Ltd.、Ahators、Hiator Technology Co. Ltd.、Autobio Diagnostics Co. Ltd.、Axiom Laboratories、Biosystems Inc.、BINDER GmBH、Roche Diagnostics、Mikroscan Technologies Inc.、Labotronics Ltd.、Hardy Diagnostics、OpGen Inc.、Meditech Technologies India Private Limited、西门子、雅培科、医学. Diagnostics、Bio-Rad Laboratories Inc.、Hologic Inc.、Quidel Corporation、Cop行业 Diagnostics Inc.、Greiner Bio-One International GmbH、Carl Zeiss AG、Nanosphere Health Sciences、GenMark Diagnostics、Meridian Bioscience Inc. 和尼康公司。
2024年血液培养检测市场最大的地区是北美。血液培养检测市场报告涵盖以下地区:亚太地区、西欧、中欧和东欧、北美、南美以及中东和非洲。
血液培养检测市场报告涵盖的国家有澳洲、巴西、中国、法国、德国、印度、印尼、日本、俄罗斯、韩国、英国和美国。
血液培养检测包括营业单位从微量采样技术和血液化学分析仪中获得的收益。市场规模包括服务提供者销售或包含在服务产品中的相关商品的价值。仅包括营业单位之间交易或销售给最终消费者的商品和服务。
Blood culture tests are diagnostic procedures designed to identify disease-causing microorganisms present in the bloodstream. These tests play a crucial role in detecting infections caused by various microorganisms such as bacteria, yeast, and other foreign invaders in a blood sample.
The primary methods employed in blood culture tests include conventional/manual methods and automated methods. The conventional or manual method is utilized to detect invaders like bacteria, yeast, and other microorganisms in a blood specimen. Manual testing involves the hands-on examination and interpretation of results by skilled testers. Blood culture products encompass consumables, instruments, and software and services that leverage technologies such as culture-based technology, molecular technologies, microarrays, PCR (polymerase chain reaction), PNA-FISH (peptide nucleic acid - fluorescent in situ hybridization), and proteomics technology. These technologies are applied in the detection of bacteremia, fungemia, and mycobacterial infections. Blood culture tests are commonly utilized by hospital laboratories, reference laboratories, academic research laboratories, and other testing facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The blood culture tests market research report is one of a series of new reports from The Business Research Company that provides blood culture tests market statistics, including blood culture tests industry global market size, regional shares, competitors with a blood culture tests market share, detailed blood culture tests market segments, market trends and opportunities, and any further data you may need to thrive in the blood culture tests industry. This blood culture tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The blood culture tests market size has grown rapidly in recent years. It will grow from $6.79 billion in 2024 to $7.51 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to increase in prevalence of infectious diseases, aging population, advances in healthcare infrastructure, rise in research and development.
The blood culture tests market size is expected to see rapid growth in the next few years. It will grow to $12.9 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to rising hospital-acquired infections, growing demand for point-of-care (poc) testing, increased healthcare spending, regulatory approvals. Major trends in the forecast period include telemedicine and remote testing, automation and ai, multiplex testing, sepsis management, infectious disease surveillance.
The forecast of 14.5% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through tariffs on enriched culture media and automated detection sensors, sourced from key regions such as Belgium and Sweden, which could lead to reduced availability of sepsis diagnostics and higher testing costs.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising incidence of infectious diseases is expected to drive the growth of the blood culture test market. Infectious diseases are caused by pathogens such as viruses, bacteria, fungi, and parasites. These harmful microorganisms can enter the body from external sources or through contact with an infected individual. Diseases like COVID-19, tuberculosis, the flu, measles, HIV, and strep throat can cause temporary discomfort, severe tissue damage, or even death. The World Health Organization identifies infectious diseases as the second leading cause of death globally. This increase in infectious disease cases has fueled the demand for blood culture tests, which help determine whether a patient has bacteremia or septicemia, potentially life-threatening conditions. For example, in August 2024, according to a report by the UK Health Security Agency, as of December 31, 2022, there were 3,732 confirmed mpox cases in the UK, primarily in England. By May 31, 2023, 21 additional cases were reported, mainly in England, with one in Scotland. As a result, the growing incidence of infectious diseases is driving demand for blood culture tests.
The rise in antibiotic resistance is expected to drive the growth of the blood culture test market in the future. Antibiotic resistance refers to the ability of bacteria, viruses, or other microorganisms to resist the effects of antibiotics or antimicrobial drugs that were previously effective in treating infections caused by these organisms. The increase in antibiotic-resistant infections requires more comprehensive diagnostic testing, including blood culture tests, to identify the most effective treatment options. For example, in November 2023, according to a report from the World Health Organization, a US-based intergovernmental organization, antibiotic-resistant infections are projected to increase from $1 trillion in 2030 to between $1 trillion and $3.4 trillion by 2050. Thus, the rising demand due to increasing antibiotic resistance is contributing to the growth of the blood culture test market.
Technological innovation emerges as a prominent trend influencing the blood culture test market. In the dynamic landscape of pharmaceuticals, biologics, nutraceuticals, and medical devices, innovation is key to meeting evolving industry requirements. The imperative to bring new products to market efficiently and cost-effectively has led manufacturers to develop cutting-edge blood culture testing technologies. Notably, Labcorp introduced the Labcorp OnDemandTM at-home collection kit in May 2022. This innovative kit utilizes dried blood technology to measure hemoglobin A1c from a small blood sample, providing users with insights into their average blood sugar levels over time. Technological advancements like this not only enhance accuracy and safety but also enable individuals to monitor their health conveniently from the comfort of their homes, fostering the growth of the blood culture test market.
Major companies in the organic blood culture tests market are focusing on developing advanced technologies, such as clinical chemistry technologies, to improve diagnostic accuracy, decrease turnaround times, and enhance patient management through integrated testing solutions that deliver comprehensive insights into infections and related health issues. Clinical chemistry technologies refer to diagnostic methods and instruments utilized to analyze bodily fluids, primarily blood, to measure chemical components and evaluate health conditions. For example, in April 2024, Mindray Medical International Limited, a medical device company based in China, launched mid-volume laboratories. These innovations demonstrate Mindray's dedication to supporting mid-volume laboratories by offering simple yet effective solutions that boost diagnostic capabilities while meeting the growing demands of healthcare providers.
In April 2022, BioMerieux India Pvt Ltd, a provider of in vitro diagnostic solutions based in India, acquired Specific Diagnostics for an undisclosed amount. This acquisition aims to improve public health by delivering innovative in vitro diagnostic solutions. Specific Diagnostics is an India-based company that produces the SPECIFIC REVEAL Rapid AST system for testing.
Major companies operating in the blood culture tests market include Becton, Dickinson and Company, BioMerieux SA, Thermo Fisher Scientific Inc., Luminex Corporation, Danaher Corporation, Terumo Corporation, Bruker Corporation, F. Hoffmann-La Roche AG, Biobase Biotech Co. Ltd., Scenker Biological Technology Co. Ltd., Bulldog Bio, Anaerobe Systems Inc., Himedia Laboratories Pvt. Ltd., Autobio Diagnostics Co. Ltd., Axiom Laboratories, Biosystems Inc., BINDER GmBH, Roche Diagnostics, Mikroscan Technologies Inc., Labotronics Ltd., Hardy Diagnostics, OpGen Inc., Meditech Technologies India Private Limited, Siemens Healthineers, Abbott Laboratories, Cepheid, T2 Biosystems Inc., Beckman Coulter Inc., Accelerate Diagnostics, Bio-Rad Laboratories Inc., Hologic Inc., Quidel Corporation, Copan Diagnostics Inc., Greiner Bio-One International GmbH, Carl Zeiss AG, Nanosphere Health Sciences, GenMark Diagnostics, Meridian Bioscience Inc., Nikon Corporation
North America was the largest region in the blood culture tests market in 2024. The regions covered in the blood culture tests market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the blood culture tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The blood culture tests include revenues earned by entities by micro sampling technology and blood chemistry analyzer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Blood Culture Tests Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on blood culture tests market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for blood culture tests ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The blood culture tests market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.